This potential acquisition may indicate Eli Lilly's strategic expansion into the cancer biotech market. The deal could strengthen the company's portfolio and suggest a growing trend of pharmaceutical companies investing in cancer research and development.
Pharmaceutical Giant Expands Cancer Portfolio
Eli Lilly is nearing a deal to acquire Kelonia Therapeutics, a cancer biotech company, for over $2 billion. The acquisition, which could be finalized as soon as Monday, is part of Eli Lilly’s efforts to expand its cancer treatment portfolio. According to people familiar with the matter, the deal price may include additional consideration if Kelonia reaches certain milestones. This development was reported by The Wall Street Journal.
This potential acquisition may indicate Eli Lilly's strategic expansion into the cancer biotech market. The deal could strengthen the company's portfolio and suggest a growing trend of pharmaceutical companies investing in cancer research and development.
Pharmaceutical Giant Expands Cancer Portfolio
Eli Lilly is nearing a deal to acquire Kelonia Therapeutics, a cancer biotech company, for over $2 billion. The acquisition, which could be finalized as soon as Monday, is part of Eli Lilly’s efforts to expand its cancer treatment portfolio. According to people familiar with the matter, the deal price may include additional consideration if Kelonia reaches certain milestones. This development was reported by The Wall Street Journal.